# South Korea Organ On Chip Market

> South Korea Organ-On-Chip Market Research Report: Size, Share, Trend Analysis By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Applications (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.09%
- **2024:** $ 8.21 Million
- **2025:** $ 8.79 Million
- **2035:** $ 17.44 Million
- **Key Players:** Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB)

**Report ID:** MRFR/MED/49550-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-organ-on-chip-market-51307

---

## Market Summary

## **South Korea Organ-On-Chip Market Overview:**

As per MRFR analysis, the South Korea Organ-On-Chip Market Size was estimated at 1.35 (USD Million) in 2023. The South Korea Organ-On-Chip Market Industry is expected to grow from 1.51(USD Million) in 2024 to 13.71 (USD Million) by 2035. The South Korea Organ-On-Chip Market CAGR (growth rate) is expected to be around 22.248% during the forecast period (2025 - 2035).

### **Key South Korea Organ-On-Chip Market Trends Highlighted**

The South Korea Organ-On-Chip market is actively expanding due to growing biotechnological innovations and an increasing need for effective preclinical drug testing. The existing research environment in the country is well developed, including government funded ones such as the Korea National Research Institute of Health. As emphasized by market opportunities, there is a focus on tailored medical solutions, less dependency on animal testing, more accurate predictive response testing, and more organ-on-chip technology. Moreover, the newfound shift towards collaboration between academia and industry also contributed to developments in this market by allowing faster application of research.

Many local manufacturers could capitalize Organ-on-Chip technology by teaming up with drug development projects because there are ample opportunities in the South Korean market. Also, the increased attention towards regulation in the drug development cycle Opening new opportunities for organ-on-chip technology in early-stage evaluation. South Korea is also experiencing a wave of public and private funding aimed at bioengineering which is a welcome addition given the global movement towards sustainable and ethical healthcare. The recent governmental funding initiatives aimed at supporting startups and innovation in biotechnology is a positive change for organ-on-chip solutions.

Such a change supports the speedy advancement of new product development and boosts the global competitive stance of South Korean businesses. The development of digital health platforms along with the merger of artificial intelligence with organ-on-chip systems technologies are remarkable also, which may change the fight regarding a given healthcare service or South Korea's leadership position in this industry.

## **South Korea Organ-On-Chip Market Drivers**

### Increasing Investment in Biotechnology and Research

The South Korea Organ-On-Chip Market Industry is experiencing substantial growth due to increased investments in biotechnology and Research and Development (R&D) initiatives. The South Korean government has committed over 1.5 trillion KRW to boost biotechnology sectors through funds and programs aimed at innovation and start-ups. Major biotechnology firms like Celltrion and Samsung Biologics are also ramping up their research efforts, pushing forward the development of organ-on-chip technologies that enhance drug testing and disease modeling.This uptick in funding and interest facilitates a conducive environment for innovations in organ-on-chip systems, exemplifying the potential applications in personalized medicine and toxicology testing.

According to the Ministry of Science and ICT, there was a 25% increase in biotechnology investments from 2020 to 2022, fuelling advancements in organ-on-chip technologies.

### Growing Demand for Personalized Medicine

The rising demand for personalized medicine in South Korea is significantly driving the expansion of the South Korea Organ-On-Chip Market Industry. With a population increasingly aware of tailored healthcare solutions, there is a notable trend towards treatments that consider individual genetic profiles. The Korea Biomedical Review highlights that about 40% of South Korean patients express a preference for personalized treatments, a figure which has steadily increased over the last 5 years.Organizations such as the Korea Health Industry Development Institute are promoting initiatives aimed at bridging the gap between traditional medicine and personalized therapeutic interventions.

Organ-on-chip technology is central to this trend, facilitating human-relevant drug tests and disease modeling, thereby supporting the development of customized medications.

### Regulatory Pressure for Alternative Testing Methods

In South Korea, there is rising regulatory pressure for the adoption of alternative testing methods, such as organ-on-chip technologies, to replace traditional animal testing. The South Korean government has aligned its policies with ethical standards and sustainability goals, urging pharmaceutical companies to transition away from animal models by implementing innovative testing alternatives.

The Ministry of Food and Drug Safety has indicated that regulations will be updated to support and fast-track the utilization of organ-on-chip systems in preclinical phases, emphasizing reduced costs and increased efficiency.The increasing ethical awareness combined with a 30% reduction in time required for drug development with organ-on-chip technology reinforces its relevance in meeting regulatory requirements for safer testing methodologies.

### Advancements in Microfabrication Technologies

Technological advancements in microfabrication methods are a pivotal driver of the South Korea Organ-On-Chip Market Industry. These advancements are enabling the fabrication of more sophisticated organ-on-chip systems that replicate human tissues accurately. South Korean research institutions like POSTECH and KAIST have pioneered developments in microfluidics and 3D bioprinting technologies that are essential for producing complex organ models.

Recent reports indicate that microfluidics in organ-on-chip systems have improved connectivity of cells by 65%, hence enhancing the physiological relevance of these models.As these methods become increasingly capable, they drive the market demand for more precise tools required by researchers in drug discovery and toxicological assessments.

## **South Korea Organ-On-Chip Market Segment Insights:**

### **Organ-On-Chip Market Organ Type Insights**

The South Korea Organ-On-Chip Market is witnessing notable evolution and innovation, particularly within the Organ Type segment. This market encompasses various organ emulations such as Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, and Human-on-Chip. Each organ model offers unique insights into physiological responses and disease mechanisms while addressing the increasing demand for more relevant preclinical testing methods. The Lung-on-Chip is essential for respiratory disease modelling, providing a platform for assessing drug responses and identifying pollutants’ effects on lung functionality.

Meanwhile, the Heart-on-Chip serves as a critical tool for cardiovascular research, simulating heart tissues to understand conditions like arrhythmias and myocardial infarctions more effectively.Liver-on-Chip technology has gained prominence due to its ability to replicate human liver functionality, crucial for drug metabolism studies and toxicology testing, thereby saving time and resources in pharmaceutical development. The Intestine-on-Chip provides significant advantages in gastrointestinal studies, allowing researchers to explore the intricacies of microbial interactions and drug absorption. Kidney-on-Chip models are instrumental in nephrology, enabling investigations into kidney diseases and the nephrotoxicity of potential therapeutic agents.

Lastly, the Human-on-Chip serves as a comprehensive platform that integrates multiple organ systems, offering holistic insights into human physiology, which is vital for personalized medicine approaches tailored to patient-specific responses.The rapid advancement and increasing adoption of these organ-on-chip technologies in South Korea are driven by innovation in bioengineering and collaborations between academia and industry, which enhance the understanding of complex biological systems. Additionally, regulatory support and funding initiatives from the South Korean government for Research and Development are propelling this market segment towards significant growth.

Overall, the Organ Type segment illustrates the market's trajectory towards more sophisticated and representative models, essential for improving the efficacy and safety of therapeutics.

### **Organ-On-Chip Market Application Insights**

The South Korea Organ-On-Chip Market, particularly in the Application segment, is witnessing notable growth and development. As the pharmaceutical and biotechnology sectors continue to evolve, the importance of Drug Discovery and Toxicology Research emerges, showcasing their pivotal roles in building innovative therapeutic solutions. Drug Discovery significantly streamlines the process of identifying viable candidates for clinical studies while reducing reliance on traditional animal testing, which aligns with ethical considerations and regulatory pressures in South Korea. Toxicology Research enables the evaluation of potential drug toxicity and adverse effects, prioritizing safety and effectiveness in drug development.

Both areas are essential for advancing the overall healthcare landscape in South Korea, as they integrate cutting-edge technology to accelerate research outcomes. Additionally, the category of Others includes evolving applications that contribute to various fields such as regenerative medicine and disease modeling, highlighting the versatility and adaptability of the organ-on-chip platforms.

The South Korea Organ-On-Chip Market is not only a reflection of technological advancements but also an alignment with the country's commitment to improving public health through innovation.Continued investment in this sector is expected, driven by a growing demand for personalized medicine and a focus on reducing development costs in the biopharma industry.

### **Organ-On-Chip Market End-User Insights**

The End-User segment of the South Korea Organ-On-Chip Market is a crucial area that significantly contributes to the overall development and utilization of this innovative technology. Pharmaceutical companies play a central role in this segment, utilizing organ-on-chip systems to enhance drug discovery and development processes, allowing for more accurate predictions of human responses to drugs. Research organizations also occupy a significant position in this landscape, as they utilize organ-on-chip platforms for advanced research applications, including personalized medicine and disease modeling, which are indispensable in understanding complex biological systems.

The ability to mimic human organ functions on a chip provides immense opportunities for enhancing patient safety and therapeutic efficacy. Additionally, other end-users encompass academic institutions and biotechnology firms that explore various applications of organ-on-chip technology, highlighting the multidimensional uses and growing acceptance across different sectors. Overall, the South Korea Organ-On-Chip Market is experiencing a transformative phase, driven by the increasing demand for innovative drug testing methods and the need for efficient and ethically responsible research tools.

## **South Korea Organ-On-Chip Market Key Players and Competitive Insights:**

The South Korea Organ-On-Chip Market has witnessed a rapid evolution, driven by advancements in biotechnology and a growing emphasis on reducing reliance on animal testing in drug development. With an increasing number of research institutions and companies focusing on in-vitro research methods, the market dynamics have become highly competitive. This niche yet impactful segment is characterized by various participants that contribute to research and development, offering innovative solutions for tissue engineering and disease modeling.

As the market matures, the emphasis on technological advancements and regulatory compliance has intensified, pushing companies to innovate continuously and improve their market positioning.Raybiotech has established a notable stronghold in the South Korean market by providing advanced organ-on-chip technology solutions aimed at enhancing biomedical research. The company is acknowledged for its innovative approaches in tissue engineering and its commitment to improving the accuracy of drug testing methodologies. Raybiotech's strengths lie in its robust research and development capabilities, which facilitate the introduction of cutting-edge products tailored to meet the specific needs of South Korean researchers and biotech firms.

The company's local partnerships with academic institutions and corporations further fortify its market presence, enabling it to stay ahead of competitors and contribute significantly to advancing organ-on-chip technologies tailored for various applications, including cancer research and drug metabolism studies.Aju Pharma, another key player in the South Korea Organ-On-Chip Market, has diversified its offerings with a focus on integrating organ-on-chip technologies within its broader pharmaceutical development ecosystem. The company stands out with its array of services that cater to the healthcare and pharmaceutical sectors, including preclinical testing and therapeutic development using organ-on-chip platforms.

Aju Pharma's market presence is bolstered by strategic mergers and acquisitions, allowing it to leverage new technologies and expertise while expanding its product portfolio. The company prides itself on its commitment to innovation, positioning itself as a thought leader in the rapidly evolving organ-on-chip space. By fostering collaborations with research institutions and maintaining a focus on quality and regulatory compliance, Aju Pharma continues to strengthen its competitiveness in the South Korean market, making significant strides in optimizing drug development processes.

### **Key Companies in the South Korea Organ-On-Chip Market Include:**

## **South Korea Organ-On-Chip Market Industry Developments**

Recent developments in the South Korea Organ-On-Chip Market have shown significant advancements, particularly with companies like Raybiotech and Organovo focusing on innovative biotechnology solutions. In July 2023, ViroMed announced progress in its organ-on-chip technology, highlighting its capability in drug testing and disease modeling. There is a growing interest among companies such as SNU Precision and iCell Gene Therapeutics, as they explore partnerships to enhance their research and development in this sector. In terms of financial growth, the Organ-On-Chip Market is experiencing an increase in valuation, driven by higher investment in healthcare technologies and increased demand for personalized medicine.

A notable acquisition in this space was by Samsung BioLogics, which acquired a minority stake in a startup specializing in organ-on-chip solutions in June 2023, aiming to bolster its capabilities in biologics. Furthermore, Aju Pharma and T&R Biofab have also been collaborating to improve their platforms for drug testing and disease modeling, reflecting an active engagement in this growing market. Over the past two years, the landscape has dramatically changed with a surge in Research and Development initiatives, indicating the sector's substantial potential and relevance within South Korea's biotechnology industry.

## **South Korea Organ-On-Chip Market Segmentation Insights**

### **Organ-On-Chip Market Organ Type****Outlook**

### **Organ-On-Chip Market Application****Outlook**

### **Organ-On-Chip Market End-User****Outlook**

## Market Drivers

### Strengthening Regulatory Frameworks

The organ on-chip market in South Korea is likely to gain momentum due to the strengthening of regulatory frameworks that support innovative technologies. Regulatory bodies are increasingly recognizing the potential of organ-on-chip devices to provide more accurate and reliable data for drug testing and safety assessments. This recognition is expected to facilitate the approval processes for organ-on-chip technologies, thereby encouraging their adoption in both research and clinical settings. The organ on-chip market may see a growth trajectory that aligns with these regulatory advancements, potentially reaching a market value of $220 million by 2029.

### Growing Awareness of Ethical Concerns

Ethical considerations surrounding animal testing are becoming increasingly prominent in South Korea, leading to a shift towards alternative methods such as organ-on-chip technologies. The organ on-chip market is poised to benefit from this growing awareness, as stakeholders seek to minimize animal use in research and development. This shift is not only ethically motivated but also aligns with regulatory trends favoring humane research practices. As a result, the market is expected to expand, with projections indicating a potential market size of $180 million by 2028, reflecting a growing preference for humane and efficient testing methods.

### Rising Demand for Personalized Medicine

The organ on-chip market in South Korea is experiencing a notable surge in demand driven by the increasing focus on personalized medicine. As healthcare shifts towards tailored treatments, the need for advanced models that accurately mimic human physiology becomes paramount. Organ-on-chip technologies offer the potential to create patient-specific models, enabling more effective drug testing and disease modeling. This trend is reflected in the market's growth, which is projected to reach approximately $200 million by 2027, indicating a compound annual growth rate (CAGR) of around 15%. The organ on-chip market is thus positioned to play a crucial role in the evolution of personalized healthcare solutions.

### Increased Investment in Biotech Research

The organ on-chip market in South Korea is benefiting from a surge in investment directed towards biotechnology research. Government initiatives and private sector funding are fostering an environment conducive to innovation in organ-on-chip technologies. This influx of capital is likely to accelerate the development of new applications and enhance the overall capabilities of organ-on-chip devices. The organ on-chip market is projected to see a growth rate of approximately 12% annually, driven by these investments. As research institutions and companies collaborate, the potential for breakthroughs in drug discovery and toxicology testing becomes increasingly viable.

### Advancements in Microfabrication Techniques

Innovations in microfabrication techniques are significantly enhancing the capabilities of the organ on-chip market in South Korea. These advancements allow for the creation of more complex and functional organ models, which can better replicate human organ behavior. Techniques such as 3D printing and soft lithography are being increasingly utilized to develop organ-on-chip devices with improved precision and scalability. As a result, the organ on-chip market is witnessing a transformation that could lead to more reliable preclinical testing and reduced reliance on animal models. The market is expected to grow substantially, with estimates suggesting a value of $150 million by 2026.

## Future Outlook

The [Organ on chip Market](https://www.marketresearchfuture.com/reports/organ-on-chip-market-8498) is projected to grow at 7.09% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

**New opportunities:**

- Development of integrated organ-on-chip platforms for drug testing
- Partnerships with pharmaceutical companies for tailored research solutions
- Expansion into educational institutions for research and training programs

By 2035, the organ on-chip market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Organ Type: Lung-on-Chip (Largest) vs. Heart-on-Chip (Fastest-Growing)

The organ on-chip segment in South Korea exhibits a diverse market share distribution, with Lung-on-Chip leading as the largest segment, followed closely by Heart-on-Chip, Liver-on-Chip, and others. These segments represent key areas of focus in research and development, reflecting the demand for personalized medicine approaches and advanced testing methods across various pharmaceutical applications.

Recent trends indicate that Heart-on-Chip is emerging as the fastest-growing segment, driven by increasing investments in cardiac research and the push for innovative drug testing methodologies. The rising prevalence of cardiovascular diseases and the need for effective therapeutic solutions are catalyzing growth in this area, while the overall segment benefits from advancements in microfluidics and bioengineering technologies.

Lung-on-Chip (Dominant) vs. Heart-on-Chip (Emerging)

Lung-on-Chip remains the dominant technology in the organ on-chip segment due to its pivotal role in respiratory disease research and drug efficacy testing. This segment is characterized by its integration of lung tissue models that closely mimic human physiology, making it invaluable for studying respiratory conditions. In contrast, Heart-on-Chip is categorized as an emerging technology driven by the rising need for cardiac safety assessments in drug development. This segment focuses on replicating the mechanical and electrical functions of heart tissues, enabling researchers to assess the impact of compounds on cardiac health effectively. Both segments reflect significant advancements in bioengineering, albeit with Lung-on-Chip currently holding a steeper market presence.

### By Application: Drug Discovery (Largest) vs. Toxicology Research (Fastest-Growing)

In the South Korea organ on-chip market, Drug Discovery currently holds the largest market share among the various applications, addressing the need for innovative and effective drug development solutions. Toxicology Research is emerging rapidly, driven by increasing regulatory pressures and the need for safer pharmaceutical products. Both applications play a crucial role in healthcare advancement, with Drug Discovery focusing on identifying potential therapeutic compounds, while Toxicology Research emphasizes safety evaluation.

The growth trends in this segment are notably influenced by technological advancements and a greater emphasis on personalized medicine. As pharmaceutical companies seek more efficient and reliable testing methods, the integration of organ-on-chip technologies is becoming essential. Furthermore, the rise in investment from both public and private sectors in biomedicine accelerates the adoption of these innovations, propelling the Toxicology Research application forward as a significant growth driver in the market.

Drug Discovery (Dominant) vs. Toxicology Research (Emerging)

The Drug Discovery application stands as the dominant player within the South Korea organ on-chip market, providing indispensable capabilities in developing and testing new medications more effectively. This application utilizes complex systems that closely mimic human biology, enabling precise assessments of drug efficacy and safety. On the other hand, Toxicology Research is positioned as an emerging sector, rapidly gaining traction due to the increasing demand for comprehensive safety assessments in drug development. This application is characterized by its ability to offer more ethical and efficient testing methods compared to traditional approaches. Both applications, while different in focus, contribute significantly to the overarching goal of improving health outcomes through advanced medical research and development.

### By End-User: Pharmaceutical Companies (Largest) vs. Research Organizations (Fastest-Growing)

In the South Korea organ on-chip market, Pharmaceutical Companies represent the largest share among the end-user segment. This dominance is driven by the increasing demand for advanced drug development technologies that enhance efficiency and precision in drug testing. Research Organizations also play a significant role, appealing to various public and private sectors that seek to leverage organ on-chip technologies for innovative research methodologies. 

The growth trends in this segment are fueled by a surge in research investments and collaborations between academic institutions and pharmaceutical firms. Additionally, the ongoing focus on personalized medicine drives Research Organizations to adopt these technologies rapidly, making them the fastest-growing segment. The increasing regulatory pressures on drug approvals further accelerates the adoption of organ on-chip systems, as they offer a more reliable alternative to animal testing.

Pharmaceutical Companies (Dominant) vs. Research Organizations (Emerging)

Pharmaceutical Companies are the dominant force in the end-user segment of the South Korea organ on-chip market, utilizing advanced technologies for drug testing and development. These companies benefit significantly from improved drug efficacy and reduced time-to-market, focusing on innovative approaches to streamline research processes. On the other hand, Research Organizations are an emerging segment, increasingly integrating organ on-chip systems into their research frameworks. They contribute substantially to the market by driving innovation and collaborating with pharmaceutical companies to explore new therapeutic applications. The blend of these two segments highlights a synergistic relationship, with Pharmaceutical Companies relying on the cutting-edge research facilitated by organizations, while Research Organizations benefit from the practical insights provided by the pharmaceutical sector.

## Competitive Benchmarking

The organ on-chip market exhibits a dynamic competitive landscape, characterized by rapid technological advancements and increasing demand for innovative drug testing solutions. Key players such as Emulate (US), TissUse (DE), and Mimetas (NL) are at the forefront, leveraging their unique capabilities to enhance product offerings. Emulate (US) focuses on creating sophisticated organ-on-chip systems that mimic human physiology, thereby facilitating more accurate drug testing. TissUse (DE) emphasizes the integration of multiple organ systems on a single chip, which allows for comprehensive pharmacokinetic studies. Mimetas (NL) is known for its 3D organoid technology, which enhances the physiological relevance of their models. Collectively, these strategies foster a competitive environment that prioritizes innovation and collaboration, driving growth in the sector.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share while also forming strategic partnerships to bolster their capabilities. This collective influence of key players is shaping a landscape where collaboration and innovation are paramount, allowing for the development of more sophisticated organ-on-chip technologies.

In October  Emulate (US) announced a partnership with a leading pharmaceutical company to develop a new organ-on-chip model aimed at accelerating drug discovery processes. This collaboration is strategically significant as it not only enhances Emulate's product portfolio but also positions the company as a key player in the pharmaceutical research domain, potentially leading to increased market penetration.

In September  TissUse (DE) launched a new multi-organ chip platform that integrates liver, kidney, and heart tissues, designed to provide a more holistic view of drug metabolism and toxicity. This development is crucial as it addresses the industry's need for more comprehensive testing models, thereby enhancing TissUse's competitive edge in the market.

In August  Mimetas (NL) secured €5 million in funding to expand its research and development capabilities, focusing on enhancing its organoid technology. This financial boost is likely to accelerate innovation within the company, allowing it to refine its offerings and maintain a competitive advantage in a rapidly evolving market.

As of November  current trends in the organ on-chip market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into research processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of agility and responsiveness in this burgeoning market.

## Recent News & Developments

Recent developments in the South Korea Organ-On-Chip Market have shown significant advancements, particularly with companies like Raybiotech and Organovo focusing on innovative biotechnology solutions. In July 2023, ViroMed announced progress in its organ-on-chip technology, highlighting its capability in drug testing and disease modeling. There is a growing interest among companies such as SNU Precision and iCell Gene Therapeutics, as they explore partnerships to enhance their research and development in this sector. In terms of financial growth, the Organ-On-Chip Market is experiencing an increase in valuation, driven by higher investment in healthcare technologies and increased demand for personalized medicine.

A notable acquisition in this space was by Samsung BioLogics, which acquired a minority stake in a startup specializing in organ-on-chip solutions in June 2023, aiming to bolster its capabilities in biologics. Furthermore, Aju Pharma and T&R Biofab have also been collaborating to improve their platforms for drug testing and disease modeling, reflecting an active engagement in this growing market. Over the past two years, the landscape has dramatically changed with a surge in Research and Development initiatives, indicating the sector's substantial potential and relevance within South Korea's biotechnology industry.

## Report Scope

| MARKET SIZE 2024 | 8.21(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 8.79(USD Million) |
| MARKET SIZE 2035 | 17.44(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.09% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB) |
| Segments Covered | Organ Type, Application, End-User |
| Key Market Opportunities | Advancements in organ-on-chip technology enhance drug testing efficiency and reduce reliance on animal models. |
| Key Market Dynamics | Rising demand for organ-on-chip technology drives innovation and regulatory support in South Korea's biotechnology sector. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the organ on-chip market in South Korea as of 2024?**
A: The organ on-chip market in South Korea was valued at $8.21 Million in 2024.

**Q: What is the projected market valuation for the organ on-chip market in South Korea by 2035?**
A: The projected valuation for the organ on-chip market in South Korea is $17.44 Million by 2035.

**Q: What is the expected CAGR for the organ on-chip market in South Korea during the forecast period 2025 - 2035?**
A: The expected CAGR for the organ on-chip market in South Korea during the forecast period 2025 - 2035 is 7.09%.

**Q: Which organ-on-chip segments are expected to show the highest growth in South Korea?**
A: The Lung-on-Chip segment is expected to grow from $1.64 Million in 2024 to $3.5 Million by 2035.

**Q: What are the key applications driving the organ on-chip market in South Korea?**
A: Drug Discovery is a key application, projected to grow from $3.29 Million in 2024 to $7.12 Million by 2035.

**Q: Who are the leading companies in the South Korean organ on-chip market?**
A: Key players in the market include Emulate, TissUse, Mimetas, Organovo, Synlogic, Hesperos, InSphero, and Reinnervate.

**Q: What is the market size for the Heart-on-Chip segment in South Korea?**
A: The Heart-on-Chip segment was valued at $1.24 Million in 2024 and is projected to reach $2.7 Million by 2035.

**Q: How does the Kidney-on-Chip segment perform in the South Korean market?**
A: The Kidney-on-Chip segment was valued at $1.0 Million in 2024 and is expected to grow to $2.2 Million by 2035.

**Q: What is the market size for the end-user segment of pharmaceutical companies in South Korea?**
A: The end-user segment for pharmaceutical companies was valued at $3.29 Million in 2024 and is projected to reach $7.12 Million by 2035.

**Q: What is the growth outlook for the Toxicology Research application in the organ on-chip market?**
A: The Toxicology Research application is expected to grow from $2.46 Million in 2024 to $5.29 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-organ-on-chip-market-51307*